Tasly Pharmaceutical Group , Ltd Overview
Get informed when a big investor buys or sells
+ Follow9.36%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Tasly Pharmaceutical Group , Ltd (600535.SS) currently reports a ROE of 9.36%. That is below the sector sector average of 11.85%. Use the charts on this page to explore Tasly Pharmaceutical Group , Ltd's ROE history and peer comparisons.
Tasly Pharmaceutical Group , Ltd's ROE of 9.36% is lower than the its sector sector average of 11.85%. That is roughly 21.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Tasly Pharmaceutical Group , Ltd's current 9.36% should be judged against industry norms (sector average: 11.85%) and against 600535.SS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 9.36%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.85%. From there, open related valuation or income-statement pages for Tasly Pharmaceutical Group , Ltd, and consider following 600535.SS for alerts when major investors trade the stock.
